Skip to content
Home/Companies/Pharma/Synthon
Synthon

Synthon

Pharma·Netherlands·Exited 2024·Held 5yr
Entry
2019
Hold
5yr
Exit
2024

Who owns Synthon?

Synthon is a Dutch Pharma company, now owned by Goldman Sachs Alternatives, which acquired it in 2024 from BC Partners.

Hand-verified · updated 2026-09-30

Open JSON · CC-BY
BC Partners
Investor
BC Partners
BC European Capital X · 2018 · Buyout

Key facts

HQNetherlands
SectorPharma
Websitewww.synthon.com
Exit Type
Trade Sale
Buyer
Goldman Sachs Alternatives
Exit Year
2024

More from BC European Capital X

Other portfolio companies in the same fund.

Keesing Media Group
Keesing Media Group
Active
ConsumerNetherlands· 2021
Ponroy Santé (Havea Group)
Active
HealthcareFrance· 2021
Tentamus
Active
Business ServicesGermany· 2021
IMA
IMA
Exited 2024
IndustrialsItaly· 2020
to BDT & MSD Partners
Keesing
Keesing
Active
GamingNetherlands· 2020
Women's Care Enterprises
Women's Care Enterprises
Active
HealthcareUS· 2020

More PE-backed in Pharma

Comparable pharma deals from other GPs.

Abacus Pharmaceuticals
Abacus Pharmaceuticals
Active
The Carlyle GroupUS
AdipoPharma
AdipoPharma
Active
Capital Grand EstFrance
Advantice Health
Advantice Health
Active
TA AssociatesUS
Alcala Farma
Active
Advent InternationalSpain
Alvogen
Alvogen
Active
CVC Capital Partners
Anovo
Anovo
Active
ArdianUS

Questions

Who owns Synthon?

Synthon is now owned by Goldman Sachs Alternatives, which acquired it in 2024 from BC Partners.

When did Goldman Sachs Alternatives acquire Synthon?

Goldman Sachs Alternatives acquired Synthon in 2024, buying from BC Partners.

Who did Synthon sell to?

BC Partners sold Synthon to Goldman Sachs Alternatives in 2024 (Trade Sale).

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue